Stockreport

Alkermes Announces Initiation of Vibrance-3 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Idiopathic Hypersomnia

Alkermes plc - Ordinary Shares  (ALKS) 
Last alkermes plc - ordinary shares earnings: 4/29 07:00 am Check Earnings Report
PDF DUBLIN, April 1, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the initiation of Vibrance-3, a phase 2 clinical study evaluating the safety and effica [Read more]